SCHEMBL24700155

SCHEMBL24700155

CC1CC=C(c2ccccc2)CN1C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
UCHL1 P09936 1/20 0.42
GPR119 Q8TDV5 1/20 0.40
NAMPT P43490 1/20 0.39
NR1H2 P55055 4/20 0.39
RXRA P19793 2/20 0.39
NR1H3 Q13133 2/20 0.39
USP30 Q70CQ3 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ACKR3 P25106 1/20 0.37
MMP1 P03956 1/20 0.37
MMP13 P45452 1/20 0.37
CKS1B P61024 1/20 0.37
SKP1 P63208 1/20 0.37
SKP2 Q13309 1/20 0.37
GRM5 P41594 1/20 0.37
GRM1 Q13255 1/20 0.37
PDK4 Q16654 1/20 0.37
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23123207 0.82 ALDH1A1 (0.36) MEN1KMT2A
SCHEMBL24700152 0.80 GRM5 (0.42) UCHL1GPR119NAMPTNR1H2RXRA
SCHEMBL17843434 0.77 AGTR2 (0.44) UCHL1GPR119NAMPTNR1H2RXRA
SCHEMBL16972028 0.77 AGTR2 (0.44) UCHL1GPR119NAMPTNR1H2RXRA
SCHEMBL14095709 0.76 KIF11 (0.46) UCHL1GPR119NR1H2RXRANR1H3
SCHEMBL14095706 0.76 KIF11 (0.46) UCHL1GPR119NR1H2RXRANR1H3
SCHEMBL29035464 0.75 UCHL1 (0.46) UCHL1GPR119NAMPTNR1H2RXRA
SCHEMBL29035461 0.75 UCHL1 (0.46) UCHL1GPR119NAMPTNR1H2RXRA
SCHEMBL14262836 0.75 PDK4 (0.56) GPR119NAMPTUSP30CKS1BSKP1
SCHEMBL8404076 0.75 GPR119 (0.34) GPR119NR1H2MEN1KMT2AGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-01 US disclosed
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-01 US disclosed
CN-114901652-A Substituted saturated and unsaturated N-heterocyclic carboxamides and related compounds for the treatment of medical disorders 比亚尔R&D投资股份公司 2022-08-12 CN disclosed
EP-4031540-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Bial-R&D Investments, S.A. (PT) 2022-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GBA2, CLN6 UCHL1 525/4885GPR119 501/4885NAMPT 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.